Hormonal Changes during a Prolonged Tamoxifen Treatment in Patients with Advanced Breast Cancer

Számel, I.; Vincze, B.; Hindy, I.; Hermann, Ilona; Borvendég, J; Eckhardt, S.

doi:10.1159/000226095

Cited by 17 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A decrease has also been found [25]. A significant increase in SHBG levels was observed, as previously described [7,10,12,24], The basal PRL levels in our pop ulation of women with breast cancer were found to be higher than those of normal postmenopausal women, something that is not rare [15, 24. 26.…”

Section: Discussionsupporting

confidence: 88%

“…It has been suggested [21,24] that a possible explanation might be a direct action of tamoxifen on the ovary. How ever, the exact mechanism of this effect is presently unclear [37], The increase in SHBG that we observed can be attributed to an oestrogenic effect of tamoxifen on the liver, as SHBG has been shown to be synthesized in human hepatocytes, and mRNA coding for SHBG has been detected in the liver [38], Furthermore, in a human hepatoma cell line tamoxifen has been shown to induce SHBG mRNA [39].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sex Hormones in Postmenopausal Women with Breast Cancer on Tamoxifen

Kostoglou-Athanassiou

Ntalles²,

Gogas³

et al. 1997

Horm Res

View full text Add to dashboard Cite

In 42 postmenopausal women with breast cancer aged 48-85 (mean age 62.4) years, the blood sex hormone levels were measured before and after 6 months of tamoxifen administration (20 mg daily). Follicle-stimulating hormone and luteinizing hormone levels decreased after tamoxifen administration (p < 0.001), but remained in the postmenopausal range, oestradiol levels increased (p < 0.05), sex hormone binding globulin levels increased (p < 0.001), testosterone levels remained stable (p > 0.1), free testosterone levels decreased (p < 0.001), Δ₄-androstenedione, 17-hydroxyprogesterone, and dehydroepiandrosterone sulfate levels remained unchanged (p > 0.1), and basal prolactin levels and their response to thyrotrophin-releasing hormone injection decreased significantly (p < 0.001) after tamoxifen therapy. It is concluded that tamoxifen has many and diverse effects on sex hormone levels, and its adverse effects do not affect the biological status of the patient, except perhaps for oestradiol, that increases in some cases, whose possible effect must be studied.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Sex Hormones in Postmenopausal Women with Breast Cancer on Tamoxifen

Kostoglou-Athanassiou

Ntalles²,

Gogas³

et al. 1997

Horm Res

View full text Add to dashboard Cite

show abstract

“…Many studies have investigated the endocrine effects of tamoxifen and MPA when used as single agents in postmenopausal breast cancer patients [17][18][19].…”

Section: Discussionmentioning

confidence: 99%

Alternating tamoxifen and medroxyprogesterone acetate in postmenopausal advanced breast cancer patients — short and long term endocrine effects

Canobbio

Galligioni

Gasparini

et al. 1987

Breast Cancer Res Tr

View full text Add to dashboard Cite

The endocrine effects of alternating tamoxifen and medroxyprogesterone acetate have been evaluated in 26 post-menopausal patients with metastatic breast cancer. Endocrine evaluations included the RIA determination of plasma levels of sex-hormone binding globulin, follicle-stimulating hormone, luteinizing hormone, estradiol, prolactin, cortisol, and testosterone. The evaluation of the study parameters at different intervals during therapy indicates that with this schedule an alternate sequential effect on the endocrine system is achievable because each drug exerts its own endocrine activity that is completely reversed when the other drug is administered. We can hypothesize that the same alternate activity as seen on the endocrine system could be obtained also on other tissues and organs including tumors.

show abstract

“…Tamoxifen causes an increase in the circulating level of SHBG in postmenopausal women (202)(203)(204). This estrogen-like action would be expected to reduce the level of free (bioavailable) estradiol.…”

Section: B Indirect Actions Of Antiestrogensmentioning

confidence: 99%

“…Tamoxifen is known to produce some estrogen-like effects in postmenopausal women that result in a decrease in FSH and LH (387), an increase in SHBG (202)(203)(204)411), alterations in the plasma protein profile (423), and changes in vaginal cytology (424). However, virtually nothing is known about the long term effects of tamoxifen on the human uterus.…”

Section: Uterine Stimulationmentioning

confidence: 99%